ArticleDermatologie (Heidelberg, Germany)2026
[Successful checkpoint inhibition plus extracorporeal photopheresis in patients with metastatic melanoma and advanced Sézary syndrome].
Article in Dermatologie (Heidelberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Our case clearly demonstrates the effectiveness of combined therapy with ipilimumab and nivolumab in Sézary syndrome, which, particularly in combination with extracorporeal photopheresis (ECP) and in the context of metastatic melanoma, led to stable partial remission. The feared hyperprogression did not occur. The initial flare was successfully bridged by therapy with topical glucocorticosteroids and a short wait after the first cycle of ipilimumab and nivolumab. Over the longer term, the patient developed an immunotherapy-related lichenoid drug eruption, which ultimately led to a pause in therapy and, thus, possibly to renewed cerebral progression of the melanoma. Further clinical research on the mechanism of action of immune checkpoint inhibitors (ICI) in cutaneous T‑cell lymphoma (CTCL) is needed in order to be able to determine the appropriate patients for ICI before starting therapy. ECP could be a possible combination partner in patients with advanced CTCL.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.